The prevalence and clinical outcome of germline mutations in the BRCA1/2 and/or PALB2 genes in breast cancer patients in different ethnic groups, including populations from Turkey,26 Lebanon,27 Japan,28 Mexico,29 China,30, 31, 32 etc, have been widely reported recently. This evidence concerns the gene PALB2 and breast carcinoma.